Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

109.72 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
63 64 Next >
Fake Ozempic - FDA and Novo Nordisk Warn Against Counterfeit Ozempic Penetrating US Market Amid High Demand
The FDA on Thursday said it continues to investigate counterfeit Novo Nordisk A/S's&n 
Via Benzinga
Exposures Product Safety
7 Low-Volatility Stocks for Stable Growth in 2024
Wager on these stocks to buy for stable growth, handpicked for their low volatility and potential to weather economic headwinds. 
Via InvestorPlace
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
Which weight-loss stocks are good buys today? 
Via The Motley Fool
Looking to Invest in the Next Big Craze Like Ozempic? This 1 Emerging Field Could Be It.
Diabetes and weight-loss drugs won't be the hottest category of medicines forever. 
Via The Motley Fool
Why Novo Nordisk Stock Was Up on a Down Day for the Market
As if the company's top two products weren't popular enough, a new media report made them even more appealing. 
Via The Motley Fool
Weight Loss Drugs By Novo Nordisk, Eli Lilly Don't Deter Nestle's Coffee Demand - CEO Explains Why
Nestle S.A. (OTC: NSRGY) CEO Mark Schneider stated that despite the rising use of weight loss medications like Eli Lilly And Company's (NYSE: LLY) Zepbound and Novo Nordisk's  
Via Benzinga
These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond
Eli Lilly and Novo Nordisk are disrupting the weight-loss market with treatments like Mounjaro and Ozempic. 
Via The Motley Fool
Novo Nordisk Collaborates With India's Online Marketplace To Remove Unauthorized Wegovy Listings
IndiaMART, an online marketplace in India, has reportedly taken action to remove unauthorized listings of Novo Nordisk A/S's (NYSE: NVO) highly sought-after weight-loss drug Wegovy after engaging in... 
Via Benzinga
LifeMD expands telehealth GLP-1weight-loss service with Medifast
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing 
Via MarketBeat
3 Stocks With the Potential to Be 2024’s Company of the Year
Finding the top stocks for 2024 is like looking for a needle in a haystack. Nonetheless, some of these names could be company of the year. 
Via InvestorPlace
Obesity/Diabetes Drug Class GLP-1s' Cost-Saving Potential: Decoding Impact on Healthcare Spending
Due to the recent achievements of GLP-1s, Goldman Sachs sees significant potential for Eli Lilly And Co (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), and other companies to venture 
Via Benzinga
Wegovy's Success Spurs Novo Nordisk Foundation's Philanthropic Initiative To Enhance Respiratory Disease Vaccines
The Novo Nordisk Foundation pledged 1.8 billion Danish crowns ($265 million) toward an initiative to enhance vaccines for respiratory illnesses.  
Via Benzinga
Why Novo Nordisk Stock Is Moving Higher Today
An Indian e-commerce company is helping Novo Nordisk combat illegal sales of weight loss drug Wegovy. 
Via The Motley Fool
Topics Law Enforcement
Exposures Legal
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
2024 is going to be a sizzler in the biopharma sector. 
Via The Motley Fool
As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
Biotech stocks have had a tough run in 2023 so far. As of early November, the iShares Biotechnology ETF (IBB) was down 7.5% while the S&P 500 was up more than 14%. 
Via Benzinga
Topics ETFs
25% of Warren Buffett's Secret Portfolio Is Invested in These 3 ETFs. Here's Why They're Great Picks for 2024.
Buffett didn't personally pick these ETFs. But all three could make him money in the new year. 
Via The Motley Fool
Topics ETFs
3 Stock-Split Stocks With 51% to 128% Upside in 2024, According to Select Wall Street Analysts
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three high-flying stocks a trio of Wall Street analysts believe can soar in the... 
Via The Motley Fool
If You Had Invested $10,000 in Novo Nordisk in 2018, This Is How Much You Would Have Today
Is it too late to invest in this fast-growing pharmaceutical company? 
Via The Motley Fool
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.
Lilly's weight loss drug appears to be on the way to becoming a megablockbuster. 
Via The Motley Fool
Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering. 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The New Magnificent 7: 7 Stocks Rising to Prominence
The next magnificent 7 stocks continue to rise to prominence and offer strong returns to investors and are generally stable. 
Via InvestorPlace
Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.
Investors shouldn't be quick to discount Novo Nordisk's long-term potential. 
Via The Motley Fool
Ryan Cohen Plans to Save GameStop By Becoming Warren Buffett
Ryan Cohen's latest plan to save GME stock is transforming GameStop into Berkshire Hathaway. Will it work? 
Via InvestorPlace
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
Exposures Product Safety
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year. 
Via InvestorPlace
Obesity Drugs: Employers Embrace Virtual Healthcare to Manage Surging Costs
U.S. 
Via Benzinga
Weight Loss Drugs' Trickle Down Effect - Insurer Restrictions Create Access Challenges For Diabetes Patients
There is growing concern among some type 2 diabetes patients over challenges in obtaining reimbursement for medications like Novo Nordisk A/S's (NYSE: NVO) Ozempic amid stricter health plan  
Via Benzinga
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
Better Weight Loss Stock: Eli Lilly or Novo Nordisk?
Both of these pharma stocks have been top performers in 2023. One stock is the better long-term buy, however. 
Via The Motley Fool
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
63 64 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.